Mowla Arash, Dastgheib Seyed Ali, Razeghian Jahromi Leila
Department of Psychiatry, Substance Abuse and Mental Health Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Clin Drug Investig. 2016 Jul;36(7):539-43. doi: 10.1007/s40261-016-0399-6.
Selecting the most effective treatment for major depressive disorder (MDD) is a challenge for clinicians. The aim of this study was to compare the effects of sertraline with duloxetine on major depression signs and symptoms.
The trial was a 6-week, randomized, controlled, double-blind study. Sixty-three patients with diagnosis of MDD according to DSM-IV-TR criteria were randomly assigned to receive either duloxetine (31 patients) or sertraline (32 patients). The mean dosage of duloxetine was 55 mg/day (range 40-60 mg/day) and the mean dosage of sertraline was 146 mg/day (range 50-200 mg/day). Subjects were assessed at baseline, and at the end of week 6. Depression severity and symptoms were assessed by 21-item Hamilton Depression Rating Scale (HAM-D).
Of 63 patients who were randomized to treatment, 54 patients including 28 in the sertraline group and 26 in the duloxetine group completed the trial. The HAM-D total score for both groups was significantly reduced at the end of the trial period without significant difference from each other (p = 0.463). Of the symptoms studied, psychomotor retardation, general somatic symptoms and sexual problems improved more in the duloxetine group. On the other hand, agitation, anxiety symptoms and hypochondriasis ameliorated better in the sertraline group. There was no difference between the two groups regarding the other symptoms.
Our study shows that the antidepressant mechanism of action has influence on its effects on different signs and symptoms. Clinician awareness of an antidepressant's special effects can help in selecting appropriate medicine.
为重度抑郁症(MDD)选择最有效的治疗方法对临床医生而言是一项挑战。本研究旨在比较舍曲林与度洛西汀对重度抑郁症体征和症状的影响。
该试验为一项为期6周的随机对照双盲研究。根据《精神疾病诊断与统计手册》第四版修订版(DSM-IV-TR)标准诊断为MDD的63例患者被随机分配接受度洛西汀治疗(31例患者)或舍曲林治疗(32例患者)。度洛西汀的平均剂量为55毫克/天(范围40 - 60毫克/天),舍曲林的平均剂量为146毫克/天(范围50 - 200毫克/天)。在基线时以及第6周结束时对受试者进行评估。通过21项汉密尔顿抑郁量表(HAM-D)评估抑郁严重程度和症状。
在随机接受治疗的63例患者中,54例患者完成了试验,其中舍曲林组28例,度洛西汀组26例。试验期结束时两组的HAM-D总分均显著降低,且两组之间无显著差异(p = 0.463)。在所研究的症状中,度洛西汀组的精神运动迟缓、全身躯体症状和性功能问题改善更为明显。另一方面,舍曲林组的激越、焦虑症状和疑病症状改善更佳。两组在其他症状方面无差异。
我们的研究表明,抗抑郁药的作用机制会影响其对不同体征和症状的疗效。临床医生了解抗抑郁药的特殊效果有助于选择合适的药物。